Mersana Therapeutics, Inc. (MRSN) Just Recorded A Sigfniciant Increase

March 14, 2018 - By Hazel Jackson

The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a huge mover today! The stock increased 13.35% or $1.97 during the last trading session, reaching $16.73. About 237,224 shares traded or 135.87% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $380.66 million company. It was reported on Mar, 14 by We have $17.57 PT which if reached, will make NASDAQ:MRSN worth $19.03 million more.

Analysts await Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report earnings on March, 15. After $-0.35 actual EPS reported by Mersana Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 28.57 % negative EPS growth.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Coverage

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) earned “Buy” rating by Leerink Swann on Monday, July 24. J.P. Morgan initiated the stock with “Buy” rating in Monday, July 24 report. The firm earned “Buy” rating on Monday, July 24 by Cowen & Co.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: which released: “Mersana Therapeutics completes $75 million IPO” on June 28, 2017, also with their article: “Mersana Therapeutics Inc.” published on June 05, 2017, published: “Mersana Therapeutics to Present at Wedbush PacGrow Healthcare Conference” on August 09, 2017. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: and their article: “Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals” published on January 08, 2018 as well as‘s news article titled: “Mersana Therapeutics Kicks Off A Major IPO Week” with publication date: June 26, 2017.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $380.66 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.